Olema Pharmaceuticals Inc (NASDAQ: OLMA) is -5.32% lower on its value in year-to-date trading and has touched a low of $4.60 and a high of $16.77 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OLMA stock was last observed hovering at around $5.14 in the last trading session, with the day’s gains setting it 0.38%.
Currently trading at $5.52, the stock is -4.28% and -33.71% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing 7.39% at the moment leaves the stock -49.57% off its SMA200. OLMA registered -52.41% loss for a year compared to 6-month loss of -62.40%. The firm has a 50-day simple moving average (SMA 50) of $8.4472 and a 200-day simple moving average (SMA200) of $10.97445.
The stock witnessed a -17.86% gain in the last 1 month and extending the period to 3 months gives it a -52.94%, and is 5.34% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.99% over the week and 9.42% over the month.
Olema Pharmaceuticals Inc (OLMA) has around 74 employees, a market worth around $377.20M and $0.00M in sales. Distance from 52-week low is 20.00% and -67.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.50%).
The EPS is expected to shrink by -7.49% this year
193.0 institutions hold shares in Olema Pharmaceuticals Inc (OLMA), with institutional investors hold 89.19% of the company’s shares. The shares outstanding are 57.29M, and float is at 55.56M with Short Float at 18.72%. Institutions hold 86.32% of the Float.
The top institutional shareholder in the company is BVF INC/IL with over 9.14 million shares valued at $98.85 million. The investor’s holdings represent 16.2322 of the OLMA Shares outstanding. As of 2024-06-30, the second largest holder is PARADIGM BIOCAPITAL ADVISORS LP with 7.9 million shares valued at $85.52 million to account for 14.0428 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 4.0 million shares representing 7.107 and valued at over $43.28 million, while BLACKROCK INC. holds 7.1062 of the shares totaling 4.0 million with a market value of $43.27 million.
Olema Pharmaceuticals Inc (OLMA) Insider Activity
The most recent transaction is an insider purchase by Bain Capital Life Sciences Inv, the company’s 10% Owner. SEC filings show that Bain Capital Life Sciences Inv bought 300,000 shares of the company’s common stock on Jan 08 ’25 at a price of $5.76 per share for a total of $1.73 million. Following the purchase, the insider now owns 7.8 million shares.
Olema Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 17 ’24 that Graham G. Walmsley (Director) sold a total of 700,761 shares of the company’s common stock. The trade occurred on Dec 17 ’24 and was made at $6.75 per share for $4.73 million. Following the transaction, the insider now directly holds 0.0 shares of the OLMA stock.
Still, SEC filings show that on Dec 13 ’24, Logos Opportunities Fund I LP (Affiliate) Proposed Sale 700,761 shares at an average price of $6.75 for $4.73 million. The insider now directly holds shares of Olema Pharmaceuticals Inc (OLMA).
